Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. The SURPASS-5 randomized clinical trial
Dahl D, Onishi Y, Norwood P, et al.
JAMA. 2022;327(6):534-545.
Leggi
Dahl D, Onishi Y, Norwood P, et al.
JAMA. 2022;327(6):534-545.
Leggi
Chipkin SR
JAMA. 2022;327(6):529-530.
Leggi
Dawwas GK, Flory JH, Hennessy S et al.
Diabetes Care. 2022;dc212177
Leggi
Moss AC, Robert AJ, Yi-Frazier JP, et al.
Diabetes Care. 2022;dc211553
Leggi
Kadowaki T, Isendahl J, Khalid U, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00008-0.
Leggi
Raverdy V, Cohen RV, Caiazzo R, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00005-5
Leggi
Chairistanidou C, Karatzi K, Karaglani E, et al.
NMCD. Pub. online 8 February 2022
Leggi
Cousin E, Duncan BB, Stein C, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(21)00349-1
Leggi
Zhang R, Mamza JB, Morris T, et al.
BMC Med. 2022;20(1):63.
Leggi
Tonon F, Candido R, Toffoli B, et al.
NMCD. Pub. online 9 February 2022
Leggi